A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic

American Journal of Medicine

Volumn 105, Issue 2, 1998, Pages 100-105

  O'Connor, Patrick G ^a   Oliveto, Alison H ^a   Shi, Julia M ^a   Triffleman, Elisa G ^a   Carroll, Kathleen M ^a   Kosten, Thomas R ^a   Rounsaville, Bruce J ^a   Pakes, Juliana A ^a   Schottenfeld, Richard S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; FEMALE; HUMAN; MALE; METHADONE TREATMENT; PATIENT COUNSELING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SUBLINGUAL DRUG ADMINISTRATION; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE FACILITIES; BUPRENORPHINE; CHI-SQUARE DISTRIBUTION; COCAINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; NARCOTIC ANTAGONISTS; PATIENT DROPOUTS; PRIMARY HEALTH CARE; STATISTICS, NONPARAMETRIC; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 0032144499     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00194-6     Document Type: Article

References (52)

1. 1. Primm BJ. Future outlook: treatment improvement. In: Lowinson JH, Ruiz P, Millman RB, et al, eds. Substance Abuse: A Comprehensive Textbook. 2nd ed. Baltimore: Williams and Wilkins; 1992:612-626.
2. 2. Dole VP. On federal regulation of methadone treatment. JAMA. 1995;274:1307.
3. 3. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical progress: medical care for injection drug users with human immunodeficiency virus infection. NEJM. 1994;331:450-459.
4. 4. Stein MD. Medical complications of intravenous drug use. J Gen Intern Med. 1990;5:249-257.
5. 5. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med. 1993;119:1017-1028.
6. 6. Fleming M, Rivo M, Kahn R. Tobacco, alcohol, and drug use in primary care: prevalence, treatment and costs. In: Sirca C, ed. Training About Alcohol and Substance Abuse for All Primary Care Physicians. New York: Josiah Macy Jr. Foundation; 1995.
7. 7. O'Connor PG, Waugh ME, Carroll KM, et al. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med. 1995;10:255-260.
8. 8. O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997;127:526-530.
9. 9. Novick DM, Pascarelli EF, Joseph H, et al. Methadone maintenance patients in general medical practice. A preliminary report. JAMA. 1988;259:3299-3302.
10. 10. Novick DM, Richman BL, Friedman JM, et al. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend. 1993;33:235-245.
11. 11. National Institute on Drug Abuse. Methadone in maintenance and detoxification: joint revisions of conditions for use. Fed Regist. 1989;54(40):8954-8971.
12. 12. Rettig RA, Yarmolinsky A. Federal Regulation of Methadone Treatment. Washington, DC: Institute of Medicine, National Academy Press; 1995.
13. 13. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA. 1995;273:1619-1620.
14. 14. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025-1030.
15. 15. Leander JD. Opioid agonist and antagonist behavioral effects of buprenorphine. Br J Pharmacol. 1983;78:607-615.
16. 16. Mello NK, Bree MP, Mendelson JH. Reinforcing properties of buprenorphine: a behavioral analysis. NIDA Res Monogr. 1981;34: 36-42.
17. 17. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
18. 18. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358-364.
19. 19. Kajiwara M, Aoki K, Ishii K, et al. Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations. Jpn J Pharmacol. 1986;40:95-101.
20. 20. Kosten TR, Kleber HD, Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry. 1989;26:637-639.
21. 21. Carroll ME, Carmona GN, May SA, et al. Buprenorphine's effects on self-administration of smoked cocaine base and orally delivered phencyclidine, ethanol and saccharin in rhesus monkeys. J Pharmacol Exp Ther. 1992;261:26-37.
22. 22. Johnson RE, Eissenberg T, Stitzer ML, et al. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 1995;40:27-35.
23. 23. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci. 1994;54:1215-1228.
24. 24. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580.
25. 25. O'Connor PG, Oliveto AH, Shi JM, et al. A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse. 1996;22:523-531.
26. 26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
27. 27. O'Connor PG, Molde S, Henry S, et al. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med. 1992;93:382-386.
28. 28. Fawcett J, Epstein P, Fiester SJ, et al. Clinical management - imipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 1978;23:309-324.
29. 29. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994;51:177-187.
30. 30. Monti PM, Abrams DB, Kadden RM, Cooney NL. Treating Alcohol Dependence. New York: Guilford Press; 1989.
31. 31. Avants SK. Coping Skills Training for Methadone-maintained Patients (unpublished manual). 1993.
32. 32. Poklis A. Evaluation of TDx cocaine metabolite assay. J Anal Toxicol. 1987;11:228-230.
33. 33. Kosten TR, Rounsaville BJ, Kleber HD. Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. Am J Drug Alcohol Abuse. 1985;11:1-10.
34. 34. Dawson-Sanders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, Conn: Appleton & Lang; 1990.
35. 35. Selvin S. Statistical Analysis of Epidemiologic Data. New York: Oxford University Press; 1991.
36. 36. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry. 1993;50:739-750.
37. 37. Novick DM, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994;9:127-130.
38. 38. McCrady BS, Langenbucher JW. Alcohol treatment and health care system reform. Arch Gen Psychiatry. 1996;53:737-746.
39. 39. Babor TF, Grant M, Acuda W, et al. A randomized clinical trial of brief interventions in primary care: summary of a WHO project. Addiction. 1994;89:657-678.
40. 40. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction. 1993;88:315-335.
41. 41. WiIk AI, Jensen NM, Havighurst TC. Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med. 1997;12:274-283.
42. 42. Fleming MF, Barry KL, Manwell LB, et al. Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. JAMA. 1997;277: 1039-1045.
43. 43. Callahan CM, Hui SL, Nienaber NA, et al. Longitudinal study of depression and health services use among elderly primary care patients. J Am Geriatr Soc. 1994;42:833-888.
44. 44. Fasching P, Derfler K, Maca T, et al. Feasibility and efficacy of intensive insulin therapy in type 1 diabetes mellitus in primary care. Diabet Med. 1994;11:836-842.
45. 45. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Pub Health Rep. 1993;108:492-500.
46. 46. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269: 1953-1959.
47. 47. Schottenfeld RS, Pakes JR, Olivette A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713-720.
48. 48. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401-407.
49. 49. Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry. 1993;34(1-2):66-74.
50. 50. Lewis DC. The role of internal medicine in addiction medicine. J Addict Dis. 1996;15:1-17.
51. 51. Babor TF, Ritson EB, Hodgson RJ. Alcohol-related problems in the primary health care setting: a review of early intervention strategies. Br J Addict. 1986;81:23-46.
52. 52. Samet JH, Saitz R, Larson MJ. A case for enhanced linkage of substance abusers to primary medical care. Substance Abuse. 1996;17: 181-182.